This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact The Epoch Times Reprints.
In this handout photo released by the University of Oxford, a volunteer participates in the CCP virus vaccine trial in Oxford, England, on July 7, 2020. The Canadian Press/AP-University of Oxford via AP
A vaccine under development has shown promise due to its producing a good immune response and low side effects in older people who are among those most vulnerable to the CCP virus.
The vaccine candidate, AZD1222, is being developed by Oxford University in partnership with the Cambridge based pharmaceutical giant, AstraZeneca.
